Should I buy or sell Alkermes stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares. View ALKS analyst ratings or view top-rated stocks .

What is Alkermes' stock price target for 2024?

10 Wall Street analysts have issued 1-year price objectives for Alkermes' stock. Their ALKS share price targets range from $25.00 to $50.00. On average, they anticipate the company's share price to reach $35.25 in the next year. This suggests a possible upside of 46.8% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts .

How have ALKS shares performed in 2024?

Alkermes' stock was trading at $27.74 at the beginning of 2024. Since then, ALKS stock has decreased by 13.4% and is now trading at $24.02. View the best growth stocks for 2024 here .

When is Alkermes' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our ALKS earnings forecast .

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) posted its quarterly earnings data on Thursday, February, 15th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.51 by $0.29. The firm earned $377.50 million during the quarter, compared to analyst estimates of $362.78 million. Alkermes had a trailing twelve-month return on equity of 16.10% and a net margin of 21.39%. The business's quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.02) EPS.

What ETFs hold Alkermes' stock?

ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include Subversive Mental Health ETF (SANE) , AdvisorShares Psychedelics ETF (PSIL) , iShares Neuroscience and Healthcare ETF (IBRN) , Invesco S&P SmallCap Health Care ETF (PSCH) , Horizon Kinetics Medical ETF (MEDX) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , ALPS Medical Breakthroughs ETF (SBIO) and BlackRock Future Health ETF (BMED) .

How will Alkermes' stock buyback program work?

Alkermes declared that its Board of Directors has approved a share buyback program on Thursday, February 15th 2024, which authorizes the company to repurchase $400,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 8.2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its shares are undervalued.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of 2.800-2.800 for the period, compared to the consensus EPS estimate of 2.520. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com . Richard F. Pops has an approval rating of 84% among the company's employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD) , Netflix (NFLX) , Pfizer (PFE) , NVIDIA (NVDA) , AbbVie (ABBV) , Starbucks (SBUX) , Intel (INTC) , Johnson & Johnson (JNJ) and Tesla (TSLA) .

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.09%) and CWM LLC (0.00%). Insiders that own company stock include Blair Curtis Jackson , Cato T Laurencin , Christian Todd Nichols , Craig C Hopkinson, Craig C Hopkinson , David Joseph Gaffin , David W Anstice , Emily Peterson Alva , Iain Michael Brown , Michael J Landine , Nancy Wysenski , Richard F Pops , Shane Cooke and Wendy L Dixon . View institutional ownership trends .

How do I buy shares of Alkermes?

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Alkermes have any subsidiaries?

The following companies are subsidiares of Alkermes: Rodin Therapeutics. Read More

NASDAQ:ALKS

Alkermes (ALKS) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free ALKS Stock Alerts

$24.02

-0.40 (-1.64%)

(As of 04/15/2024 ET)

Compare

Today's Range: $23.92
▼
$24.60
50-Day Range: $24.02
▼
$32.56
52-Week Range: $22.01
▼
$33.71

Volume: 2.71 million shs
Average Volume: 1.91 million shs
Market Capitalization: $4.06 billion

P/E Ratio: 11.60
Dividend Yield: N/A
Price Target: $35.25

Get Alkermes alerts:

Alkermes MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 46.8% Upside
$35.25 Price Target
Short Interest: Bearish
8.48% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.17
Upright™ Environmental Score
News Sentiment: 0.47
Based on 34 Articles This Week
Insider Trading: Selling Shares
$292,718 Sold Last Quarter
Proj. Earnings Growth: -6.28%
From $2.23 to $2.09 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.80 out of 5 stars

Medical Sector

218th out of 929 stocks

Pharmaceutical Preparations Industry

88th out of 422 stocks

3.3

Analyst's Opinion

Consensus Rating
Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Alkermes has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.48% of the outstanding shares of Alkermes have been sold short.
Short Interest Ratio / Days to Cover
Alkermes has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Alkermes has recently increased by 1.85%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Alkermes does not currently pay a dividend.
Dividend Growth
Alkermes does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Alkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Alkermes is -1.17.

1.9

News and Social Media Coverage

News Sentiment
Alkermes has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 34 news articles for Alkermes this week, compared to 6 articles on an average week.
Search Interest
Only 1 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $292,718.00 in company stock.
Percentage Held by Insiders
Only 4.76% of the stock of Alkermes is held by insiders.
Percentage Held by Institutions
95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Alkermes are expected to decrease by -6.28% in the coming year, from $2.23 to $2.09 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Alkermes is 11.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.21.
Price to Earnings Ratio vs. Sector
The P/E ratio of Alkermes is 11.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 248.92.
Price to Book Value per Share Ratio
Alkermes has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Alkermes Stock (NASDAQ:ALKS)

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

ALKS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ALKS Stock News Headlines

March 19, 2024 | insidertrades.com

Alkermes plc (NASDAQ:ALKS) SVP Sells $292,717.70 in Stock

April 13, 2024 | americanbankingnews.com

Alkermes plc Forecasted to Post Q3 2025 Earnings of $0.52 Per Share (NASDAQ:ALKS)

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

April 13, 2024 | americanbankingnews.com

FY2024 EPS Estimates for Alkermes plc (NASDAQ:ALKS) Reduced by Analyst

April 12, 2024 | markets.businessinsider.com

Hold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory Challenges

April 12, 2024 | americanbankingnews.com

FY2025 EPS Estimates for Alkermes plc Raised by Zacks Research (NASDAQ:ALKS)

April 12, 2024 | americanbankingnews.com

FY2027 Earnings Forecast for Alkermes plc Issued By Leerink Partnrs (NASDAQ:ALKS)

April 11, 2024 | investing.com

Jefferies raises Alkermes stock target on positive OX2 data

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

April 11, 2024 | americanbankingnews.com

Alkermes (NASDAQ:ALKS) Shares Gap Up After Analyst Upgrade

April 10, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth Potential

April 10, 2024 | americanbankingnews.com

Alkermes (NASDAQ:ALKS) Given New $50.00 Price Target at Jefferies Financial Group

April 9, 2024 | markets.businessinsider.com

Breaking Down Alkermes: 5 Analysts Share Their Views

April 9, 2024 | msn.com

Alkermes posts early-stage win for sleeping disorder therapy (update)

April 9, 2024 | seekingalpha.com

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

April 9, 2024 | msn.com

Alkermes succeeds in early-stage trial for sleeping disorder therapy

April 9, 2024 | seekingalpha.com

Alkermes plc: Collecting The Fruits Of The 2023 Spinoff

April 9, 2024 | prnewswire.com

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

April 8, 2024 | prnewswire.com

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

March 29, 2024 | finance.yahoo.com

Investors in Alkermes (NASDAQ:ALKS) have seen favorable returns of 44% over the past three years

March 28, 2024 | nasdaq.com

Noteworthy Tuesday Option Activity: ALKS, DKNG, VRT

March 20, 2024 | investing.com

Alkermes exec sells over $290k in company shares

March 19, 2024 | msn.com

Baird starts Alkermes at outperform, citing revenue stream

March 19, 2024 | markets.businessinsider.com

The Analyst Verdict: Alkermes In The Eyes Of 4 Experts

March 18, 2024 | finance.yahoo.com

Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)

March 15, 2024 | nasdaq.com

ALKS Factor-Based Stock Analysis

March 15, 2024 | finance.yahoo.com

Alkermes (ALKS) Stock Moves -0.45%: What You Should Know

See More Headlines

Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/16/2024
Next Earnings (Estimated): 4/24/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:ALKS
CUSIP: G0176710
CIK: 1520262
Web: www.alkermes.com
Phone: (531) 772-8000
Fax: 781-890-0524
Employees: 2,100
Year Founded: 1987

Price Target and Rating

Average Stock Price Target: $35.25
High Stock Price Target: $50.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +46.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.07
Trailing P/E Ratio: 11.60
Forward P/E Ratio: 10.77
P/E Growth: N/A
Net Income: $355.76 million
Net Margins: 21.39%
Pretax Margin: 25.34%
Return on Equity: 16.10%
Return on Assets: 9.15%

Debt

Debt-to-Equity Ratio: 0.24
Current Ratio: 2.86
Quick Ratio: 2.50

Sales & Book Value

Annual Sales: $1.66 billion
Price / Sales: 2.44
Cash Flow: $2.23 per share
Price / Cash Flow: 10.76
Book Value: $7.21 per share
Price / Book: 3.33

Miscellaneous

Outstanding Shares: 169,180,000
Free Float: 161,131,000
Market Cap: $4.06 billion
Optionable: Optionable
Beta: 0.56

Social Links

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Richard F. Pops (Age 62)
Chairman & CEO
Comp: $2.3M
Mr. Blair C. Jackson (Age 51)
Interim Principal Financial Officer, Executive VP & COO
Comp: $1.05M
Mr. David Joseph Gaffin (Age 52)
Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary
Comp: $1.08M
Mr. Iain Michael Brown (Age 55)
Senior VP & CFO (Leave of Absence)
Comp: $867.75k
Dr. Craig C. Hopkinson M.D. (Age 56)
Executive VP of Research & Development and Chief Medical Officer
Comp: $1.12M
Dr. Floyd E. Bloom M.D. (Age 87)
Founder
Comp: $57.73k
Mr. Samuel J. Parisi (Age 49)
Interim Principal Accounting Officer & VP of Finance
Mr. Thomas Harvey
Chief Information Officer & Senior VP of IT
Ms. Sandra Coombs
Senior Vice President of Corporate Affairs & Investor Relations
Mr. Michael J. Landine (Age 70)
Senior VP of Corporate Development & Chief Risk Officer
Comp: $750.46k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ALKS Stock Analysis - Frequently Asked Questions

Should I buy or sell Alkermes stock right now?: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares.
View ALKS analyst ratings or view top-rated stocks.
What is Alkermes' stock price target for 2024?: 10 Wall Street analysts have issued 1-year price objectives for Alkermes' stock. Their ALKS share price targets range from $25.00 to $50.00. On average, they anticipate the company's share price to reach $35.25 in the next year. This suggests a possible upside of 46.8% from the stock's current price.
View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts.
How have ALKS shares performed in 2024?: Alkermes' stock was trading at $27.74 at the beginning of 2024. Since then, ALKS stock has decreased by 13.4% and is now trading at $24.02.
View the best growth stocks for 2024 here.
When is Alkermes' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our ALKS earnings forecast.
How were Alkermes' earnings last quarter?: Alkermes plc (NASDAQ:ALKS) posted its quarterly earnings data on Thursday, February, 15th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.51 by $0.29. The firm earned $377.50 million during the quarter, compared to analyst estimates of $362.78 million. Alkermes had a trailing twelve-month return on equity of 16.10% and a net margin of 21.39%. The business's quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.02) EPS.
What ETFs hold Alkermes' stock?: ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include Subversive Mental Health ETF (SANE), AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), Invesco S&P SmallCap Health Care ETF (PSCH), Horizon Kinetics Medical ETF (MEDX), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO) and BlackRock Future Health ETF (BMED).
How will Alkermes' stock buyback program work?: Alkermes declared that its Board of Directors has approved a share buyback program on Thursday, February 15th 2024, which authorizes the company to repurchase $400,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 8.2% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its shares are undervalued.

What guidance has Alkermes issued on next quarter's earnings?: Alkermes issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of 2.800-2.800 for the period, compared to the consensus EPS estimate of 2.520. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.
What is Richard F. Pops' approval rating as Alkermes' CEO?: 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees.
What other stocks do shareholders of Alkermes own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).
Who are Alkermes' major shareholders?: Alkermes' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.09%) and CWM LLC (0.00%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon.
View institutional ownership trends.
How do I buy shares of Alkermes?: Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Alkermes have any subsidiaries?: The following companies are subsidiares of Alkermes: Rodin Therapeutics.
Read More

This page (NASDAQ:ALKS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial